Alzamend Neuro, Inc. Stock

ALZN

US02262M6057

Biotechnology & Medical Research

Market Closed - Nasdaq 07:30:00 17/10/26 am AEDT			5-day change	1st Jan Change
1.300 ^USD	+1.56%		-2.99%	-28.57%

11/09	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
20/08	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI

Valuation: Alzamend Neuro, Inc.

Market Cap	6.27M 5.58M 5.17M 4.71M 8.87M 596M 9.03M 62.09M 24.37M 311M 23.54M 23.04M 991M	P/E 2027 *	-1.24x	P/E 2028 *	-1.49x
Enterprise Value	6.27M 5.58M 5.17M 4.71M 8.87M 596M 9.03M 62.09M 24.37M 311M 23.54M 23.04M 991M	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	97.34%	Yield 2027 *	-	Yield 2028 *	-

* Estimated data More valuation ratios

Latest news: Alzamend Neuro, Inc.

11/09	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
20/08	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI
18/08	Alzamend Neuro, Inc. Reports Phase 1/2A Lithium Imaging Data For AL001 At ISMRM Workshop	CI
05/08	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending	CI
23/07	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026	CI
22/07	Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt	CI
22/07	Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026	CI
07/04	Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001	CI
26/03	Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001	CI
17/03	Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	CI
16/03	Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital	RE
12/03	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026	CI
07/03	Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stock - SEC filing	RE

More news

Analysts' recommendations: Alzamend Neuro, Inc.

12/04/23	Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target	MT
28/12/21	Ascendiant Capital Adjusts Price Target on Alzamend Neuro to $8.25 From $8, Maintains Buy Rating	MT
02/10/21	Alzamend Neuro : Ascendiant Capital Initiates Alzamend Neuro at Buy Rating With $8 Price Target	MT

More recommendations

Press Releases: Alzamend Neuro, Inc.

20/08	Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC	PR
18/08	Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain	PR
23/07	Alzamend Neuro : Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)	PU
07/04	Alzamend Neuro : Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital	PU
26/03	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions	PR

More press releases

Managers and Directors: Alzamend Neuro, Inc.

Manager	Title	Age	Since
Stephan Jackman CEO	Chief Executive Officer	50	20/11/2018
David Katzoff DFI	Director of Finance/CFO	64	05/08/2022
Henry Nisser LAW	General Counsel	57	01/05/2019

Director	Title	Age	Since
Todd Ault CHM	Chairman	56	26/02/2016
William Horne CHM	Chairman	57	01/06/2021
Stephan Jackman BRD	Director/Board Member	50	01/09/2020

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZAMEND NEURO, INC.	+1.56%	-2.99%	-43.97%	-99.53%	6.18M
WUXI APPTEC CO., LTD.	-6.60%	-10.93%	+45.08%	+60.01%	68.98B
ARGENX SE	-4.09%	+3.12%	+3.71%	+53.50%	53.15B
LONZA GROUP AG	+0.03%	+7.21%	+12.52%	+44.46%	50.83B
IQVIA HOLDINGS INC.	-1.53%	+3.10%	+31.40%	+33.88%	44.61B
REVOLUTION MEDICINES, INC.	-5.97%	-5.40%	+259.08%	+494.98%	40.57B
BEONE MEDICINES AG	-1.34%	+5.41%	+16.74%	+106.42%	42.53B
CELLTRION, INC.	+6.53%	+8.02%	+18.98%	+54.58%	30.95B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.91%	+34.11%	-1.83%	25.44B
BIONTECH SE	-2.76%	-4.73%	-15.94%	-15.32%	22.66B
Average	-1.32%	+0.92%	+36.17%	+73.12%	37.97B
Weighted average by Cap.	-2.32%	+1.65%	+46.51%	+96.53%

See all sector performances

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâ€™s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	USD 1.300	+1.56%	15,567
15/10/26	USD 1.280	-5.19%	14,972
14/10/26	USD 1.350	0.00%	23,163
13/10/26	USD 1.350	+3.05%	18,050
12/10/26	USD 1.310	-2.24%	17,032

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.300USD

Average target price

26.00USD

Spread / Average Target

+1,900.00%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Alzamend Neuro, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alzamend Neuro, Inc.

Company calendar

Stock Market
Stocks
ALZN Stock

The best tools reserved for subscribers to boost the performance of your investments!

1 day	+1.56%
1 week	-2.99%
Current month	-24.86%
1 month	-26.97%
3 months	+5.69%
6 months	+27.45%
Current year	-28.57%

1 week	1.25	1.43
1 month	1.2	1.95
Current year	0.84	2.54
1 year	0.84	2.68
3 years	0.84	296.86
5 years	0.84	4,562.86
10 years	0.84	45,292.48

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
26/8/26	Todd Ault	Sell	Founder	-2,000	0.0417%
26/8/26	HYPERSCALE DATA, INC.	Other	Company	0	0%	-
31/7/26	HYPERSCALE DATA, INC.	Free	Company	7,500	0.1565%

	2027 *	2028 *
Net sales	-	-
Net income	-10.8M -9.61M -8.89M -8.1M -15.27M -1.03B -15.55M -107M -41.96M -535M -40.53M -39.66M -1.71B	-10.8M -9.61M -8.89M -8.1M -15.27M -1.03B -15.55M -107M -41.96M -535M -40.53M -39.66M -1.71B
Net Debt	-	-

Alzamend Neuro, Inc. Stock

Stocks

ALZN

US02262M6057

Biotechnology & Medical Research

Valuation: Alzamend Neuro, Inc.

Chart: Alzamend Neuro, Inc.

Latest news: Alzamend Neuro, Inc.

Analysts' recommendations: Alzamend Neuro, Inc.

Press Releases: Alzamend Neuro, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Alzamend Neuro, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Markets		Quality
Nasdaq	ALZN	Delayed
CBOE	ALZN	Real-time